Neurocrine Biosciences (NBIX) Operating Leases (2019 - 2026)

Neurocrine Biosciences' Operating Leases history runs 8 years deep, the most recent figure standing at $406.2 million for Q1 2026.

• Quarterly Operating Leases fell 17.62% year-over-year to $406.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $406.2 million (down 17.62% YoY) and the FY2025 annual result came in at $415.3 million, down 8.75% from the prior year.
• Operating Leases was $406.2 million for Q1 2026 at Neurocrine Biosciences, down from $415.3 million in the prior quarter.
• Across five years, Operating Leases topped out at $493.1 million in Q1 2025 and bottomed at $85.9 million in Q3 2023.
• A 5-year average of $260.9 million and a median of $286.2 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2023 — Operating Leases decreased 24.58% — and 2024, when it soared 233.18%.
• Neurocrine Biosciences' Operating Leases stood at $93.5 million in 2022, then jumped by 102.99% to $189.8 million in 2023, then surged by 139.78% to $455.1 million in 2024, then fell by 8.75% to $415.3 million in 2025, then fell by 2.19% to $406.2 million in 2026.
• Business Quant data shows NBIX's Operating Leases at $406.2 million in Q1 2026, $415.3 million in Q4 2025, and $428.4 million in Q3 2025.